LF
MCID: LSS003
MIFTS: 53

Lassa Fever (LF)

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lassa Fever

MalaCards integrated aliases for Lassa Fever:

Name: Lassa Fever 11 58 75 53 2 43 14 16 71 31 33
Lassa Hemorrhagic Fever 58
Lf - [lassa Fever] 33
Lf 58

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Lassa Fever

Disease Ontology: 11 A viral infectious disease that results in infection, has material basis in Lassa virus, which is transmitted by multimammate rat of the genus Mastomys. The infection has symptom fever, has symptom retrosternal pain, has symptom sore throat, has symptom back pain, has symptom cough, has symptom abdominal pain, has symptom vomiting, has symptom diarrhea, has symptom conjunctivitis, has symptom facial swelling, has symptom proteinuria (protein in the urine), and has symptom mucosal bleeding.

MalaCards based summary: Lassa Fever, also known as lassa hemorrhagic fever, is related to yellow fever and lymphocytic choriomeningitis, and has symptoms including proteinuria, vomiting and fever. An important gene associated with Lassa Fever is DAG1 (Dystroglycan 1), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Favipiravir and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include t cells, liver and monocytes, and related phenotypes are fever and increased circulating igm level

CDC: 2 Lassa fever is an animal-borne, or zoonotic, acute viral illness. It is endemic in parts of West Africa including Sierra Leone, Liberia, Guinea and Nigeria. Neighboring countries are also at risk, as the animal vector for Lassa virus, the "multimammate rat" (Mastomys natalensis) is distributed throughout the region.

Orphanet: 58 Lassa fever (LF) is a potentially severe viral hemorrhagic disease caused by Lassa virus and characterized by initial fever and malaise followed by gastrointestinal symptoms and, in severe cases, bleeding, shock and multi-organ system failure.

Wikipedia: 75 Lassa fever, also known as Lassa hemorrhagic fever (LHF), is a type of viral hemorrhagic fever caused by... more...

Related Diseases for Lassa Fever

Diseases related to Lassa Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 yellow fever 30.7 RIGI IFNB1 IFNAR1
2 lymphocytic choriomeningitis 30.7 RIGI IRF3 DAG1 CD209
3 vaccinia 30.5 IRF3 IFNB1 IFNA1 ERVW-1
4 myocarditis 30.4 IFNA1 IFIH1 DAG1 CD4
5 stomatitis 30.2 RIGI IFNB1 IFNA1 IFIH1 CD4 BST2
6 aseptic meningitis 30.2 IFNA1 CD8A CD4
7 marburg hemorrhagic fever 30.2 IFNB1 IFNA1 GTPBP1 GP2 ERVW-1 CD8A
8 rabies 30.2 RIGI LAMP1 IRF3 IFNA1
9 diarrhea 30.1 RIGI IRF3 IFNB1 IFNA1
10 meningoencephalitis 30.0 CD8A CD4 ACE2
11 plague 29.9 RIGI CD8A CD4 ACE2
12 blood platelet disease 29.9 IFNA1 CD8A CD4 ACE2
13 leprosy 3 29.8 IFNB1 CD8A CD4 CD209
14 bolivian hemorrhagic fever 29.8 RIGI MBTPS1 IFNA1 GTPBP1 GP2 ERVW-1
15 hepatitis 29.7 RIGI IRF3 IFNB1 IFNA1 IFIH1
16 ebola hemorrhagic fever 29.7 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
17 respiratory failure 29.7 IFNB1 IFNA1 CD8A CD4 ACE2
18 thrombocytopenia 29.6 RIGI IFNB1 IFNA1 IFIH1 CD4 CD209
19 zika fever 29.5 RIGI IFNB1 IFNAR1 IFNA1 ERVW-1 CD209
20 dengue disease 29.5 RIGI IFNB1 IFNAR1 IFNA1 ERVW-1 CD8A
21 viral infectious disease 29.3 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
22 measles 29.1 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
23 severe acute respiratory syndrome 28.9 RIGI IRF3 IFNB1 IFNA1 IFIH1 CD209
24 hemorrhagic disease 10.5
25 sensorineural hearing loss 10.4
26 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
27 blessig's cysts 10.4 GTPBP1 GP2
28 de quervain disease 10.4 GTPBP1 GP2
29 intestinal tuberculosis 10.4 GP2 CD4
30 st. louis encephalitis 10.3 IFNA1 ERVW-1
31 hilar lung neoplasm 10.3 CD8A CD4
32 oral tuberculosis 10.3 CD8A CD4
33 early yaws 10.3 CD8A CD4
34 ventilation pneumonitis 10.3 CD8A CD4
35 diffuse infiltrative lymphocytosis syndrome 10.3 CD8A CD4
36 wissler-fanconi syndrome 10.3 CD8A CD4
37 autoimmune lymphoproliferative syndrome, type iia 10.3 CD8A CD4
38 encephalitozoonosis 10.3 CD8A CD4
39 type 1 diabetes mellitus 23 10.3 CD8A CD4
40 cork-handlers' disease 10.3 CD8A CD4
41 typhoid fever 10.3
42 primary agammaglobulinemia 10.3
43 ross river fever 10.3 IFNB1 ERVW-1
44 follicular mucinosis 10.3 CD8A CD4
45 suppurative lymphadenitis 10.3 CD8A CD4
46 bird fancier's lung 10.3 CD8A CD4
47 listeria meningitis 10.3 IFNB1 CD8A
48 parapsoriasis 10.3 CD8A CD4
49 primary syphilis 10.3 CD8A CD4
50 alkhurma hemorrhagic fever 10.3 IFNAR1 ERVW-1

Graphical network of the top 20 diseases related to Lassa Fever:



Diseases related to Lassa Fever

Symptoms & Phenotypes for Lassa Fever

Human phenotypes related to Lassa Fever:

58 30 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001945
2 increased circulating igm level 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003496
3 menometrorrhagia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0400008
4 asthenia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0025406
5 viremia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0020071
6 nausea and vomiting 58 30 Frequent (33%) Frequent (79-30%)
HP:0002017
7 dysphagia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002015
8 muscle weakness 58 30 Frequent (33%) Frequent (79-30%)
HP:0001324
9 abdominal pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0002027
10 cough 58 30 Frequent (33%) Frequent (79-30%)
HP:0012735
11 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
12 headache 58 30 Frequent (33%) Frequent (79-30%)
HP:0002315
13 pharyngitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0025439
14 seizure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001250
15 hearing impairment 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000365
16 jaundice 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000952
17 back pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003418
18 dyspnea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002094
19 arthralgia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002829
20 conjunctivitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000509
21 sepsis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100806
22 abnormal bleeding 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001892
23 premature birth 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001622
24 diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002014
25 oliguria 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100520
26 facial edema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000282
27 shock 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031273
28 spontaneous abortion 58 Very frequent (99-80%)

Symptoms:

11 (show all 12)
  • proteinuria
  • vomiting
  • fever
  • back pain
  • abdominal pain
  • cough
  • conjunctivitis
  • diarrhea
  • sore throat
  • retrosternal pain
  • facial swelling
  • mucosal bleeding

GenomeRNAi Phenotypes related to Lassa Fever according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ACE2 BST2 CD209 CD4 CD8A DAG1
2 no effect GR00402-S-2 10.17 BST2 CD209 CD4 DAG1 ERVW-1 GTPBP1

MGI Mouse Phenotypes related to Lassa Fever:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 ACE2 BST2 CD209 CD4 CD8A DAG1
2 immune system MP:0005387 10.03 ACE2 BST2 CD209 CD4 CD8A GP2
3 renal/urinary system MP:0005367 9.97 ACE2 BST2 CD209 CD8A GP2 IFIH1
4 hematopoietic system MP:0005397 9.83 ACE2 BST2 CD209 CD4 CD8A GP2
5 integument MP:0010771 9.28 ACE2 BST2 CD4 CD8A GP2 IFIH1

Drugs & Therapeutics for Lassa Fever

Drugs for Lassa Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Favipiravir Approved, Investigational Phase 2 259793-96-9 492405
2 Pharmaceutical Solutions Phase 1
3 Vaccines Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial Active, not recruiting NCT04907682 Phase 2 Ribavirin iv;Favipiravir
2 Treatment of Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) With Intravenous Ribavirin in Department of Defense (DOD) Associated Medical Treatment Facilities: A Phase 2 Study Withdrawn NCT00992693 Phase 2 Ribavirin (Virazole) Injection
3 Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Combination With Electroporation in Healthy Volunteers in Ghana Completed NCT04093076 Phase 1 INO-4500;Placebo
4 Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers Completed NCT03805984 Phase 1 INO-4500;Placebo
5 A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase Completed NCT04055454 Phase 1
6 A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath Recruiting NCT04794218 Phase 1 rVSV∆G-LASV-GPC
7 Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Lassa Fever Patients in Nigeria: a Prospective Observational Cohort Study Completed NCT04285034
8 Study of the Seroprevalence and the Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali Completed NCT02311387
9 Observational Cohort Study of Lassa Fever Clinical Course and Prognostic Factors in an Epidemic Context in Nigeria Recruiting NCT03655561
10 Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) Recruiting NCT02483260 Ribavirin
11 Serosurvey for Prevalence and Incidence of Lassa Virus Infection in Southern Mali Recruiting NCT03783143
12 Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever Terminated NCT03889106 Ribavirin

Search NIH Clinical Center for Lassa Fever

Cochrane evidence based reviews: lassa fever

Genetic Tests for Lassa Fever

Anatomical Context for Lassa Fever

Organs/tissues related to Lassa Fever:

MalaCards : T Cells, Liver, Monocytes, Myeloid, Endothelial, Kidney, Lung

Publications for Lassa Fever

Articles related to Lassa Fever:

(show top 50) (show all 989)
# Title Authors PMID Year
1
Old World arenavirus infection interferes with the expression of functional alpha-dystroglycan in the host cell. 53 62
17761532 2007
2
O Mannosylation of alpha-dystroglycan is essential for lymphocytic choriomeningitis virus receptor function. 53 62
16254364 2005
3
Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. 53 62
16254363 2005
4
Electron microscopy of an alpha-dystroglycan fragment containing receptor sites for lymphocytic choriomeningitis virus and laminin, and use of the receptoid body as a reagent to neutralize virus. 53 62
15246261 2004
5
Viral RNA and infectious virus in mucosal specimens from guinea pigs modelling early phases of lethal and non-lethal Lassa fever. 62
35481464 2022
6
Hearing loss in outbred Hartley guinea pigs experimentally infected with Pichinde virus as a surrogate model of human mammarenaviral hemorrhagic fevers. 62
35758052 2022
7
Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys. 62
35437094 2022
8
Lassa antiviral LHF-535 protects guinea pigs from lethal challenge. 62
36402782 2022
9
Towards specie-specific ensemble vaccine candidates against mammarenaviruses using optimized structural vaccinology pipeline and molecular modelling approaches. 62
36165863 2022
10
Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. 62
36441765 2022
11
The Pan-ErbB tyrosine kinase inhibitor afatinib inhibits multiple steps of the mammarenavirus life cycle. 62
36183499 2022
12
Exotic viral hepatitis: A review on epidemiology, pathogenesis, and treatment. 62
35817222 2022
13
Ecological interactions, local people awareness and practices on rodent-borne diseases in Africa: A review. 62
36343664 2022
14
The COVID-19 Impact on the Trends in Yellow Fever and Lassa Fever Infections in Nigeria. 62
36412749 2022
15
Risk communication sources and knowledge of Lassa fever in Nigeria: An impact analysis. 62
36406662 2022
16
Lassa fever cases suffer from severe underreporting based on reported fatalities. 62
36413115 2022
17
Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults. 62
36314868 2022
18
After action review of the response to an outbreak of Lassa fever in Sierra Leone, 2019: Best practices and lessons learnt. 62
36197925 2022
19
Evaluation of Three Clinical Prediction Tools to Predict Mortality in Hospitalized Patients with Lassa Fever. 62
35895416 2022
20
Immunoinformatics analysis to design novel epitope based vaccine candidate targeting the glycoprotein and nucleoprotein of Lassa mammarenavirus (LASMV) using strains from Nigeria. 62
33719908 2022
21
Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines. 62
36298533 2022
22
Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections. 62
36148915 2022
23
Lassa Virus Countermeasures. 62
36253593 2022
24
Assessing the Brighton Collaboration Case Definition of Sensorineural Hearing Loss in Ghana. 62
36252804 2022
25
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus. 62
36288283 2022
26
Identifying immunodominant multi-epitopes from the envelope glycoprotein of the Lassa mammarenavirus as vaccine candidate for Lassa fever. 62
36451670 2022
27
Depletion of CD4 and CD8 T Cells Reduces Acute Disease and Is Not Associated with Hearing Loss in ML29-Infected STAT1-/- Mice. 62
36289695 2022
28
Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. 62
36167835 2022
29
Adapting public health response through lessons learnt: Nigeria's experience from Lassa fever and COVID-19. 62
36130796 2022
30
Lassa fever - the road ahead. 62
36097163 2022
31
Epidemiological characteristics of Lassa fever cases in Liberia: a retrospective analysis of surveillance data, 2019-2020. 62
35817283 2022
32
First confirmed diagnosis of Lassa fever in Kebbi state, northwest Nigeria: Lessons to be learned. 62
36164684 2022
33
Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. 62
35913205 2022
34
Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1. 62
35876478 2022
35
Evaluating the Biological Role of Lassa Viral Z Protein-Mediated RIG-I Inhibition Using a Replication-Competent Trisegmented Pichinde Virus System in an Inducible RIG-IN Expression Cell Line. 62
35913216 2022
36
Neutralizing Antibodies against Lassa Virus Lineage I. 62
35730904 2022
37
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. 62
35858566 2022
38
Pharmacokinetics of ribavirin in the treatment of Lassa fever: An observational clinical study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. 62
35881530 2022
39
Lassa Virus Infection: a Summary for Clinicians. 62
35395384 2022
40
Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease. 62
35296886 2022
41
Detection of Lassa Virus-Reactive IgG Antibodies in Wild Rodents: Validation of a Capture Enzyme-Linked Immunological Assay. 62
35632733 2022
42
Pathology and Pathogenesis of Lassa Fever: Novel Immunohistochemical Findings in Fatal Cases and Clinico-pathologic Correlation. 62
34463715 2022
43
Pathogens that Cause Illness Clinically Indistinguishable from Lassa Fever, Nigeria, 2018. 62
35226800 2022
44
Persistent viral shedding after acute Lassa fever: thorough evidence arouses more noteworthy concerns. 62
35544091 2022
45
CD4 T-cell depletion prevents Lassa fever associated hearing loss in the mouse model. 62
35605008 2022
46
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. 62
35613585 2022
47
Beyond Lassa Fever: Systemic and structural barriers to disease detection and response in Sierra Leone. 62
35587495 2022
48
Emerging Viral Infections, Hypertension, and Cardiovascular Disease in Sub-Saharan Africa: A Narrative Review. 62
35272495 2022
49
COVID-19 and Lassa fever in Nigeria: A deadly alliance? 62
35108609 2022
50
A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands. 62
35167968 2022

Variations for Lassa Fever

Expression for Lassa Fever

Search GEO for disease gene expression data for Lassa Fever.

Pathways for Lassa Fever

Pathways related to Lassa Fever according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 BST2 CD209 CD4 CD8A IFI30 IFIH1
2
Show member pathways
13.71 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
3
Show member pathways
13.19 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFI30
4
Show member pathways
13.08 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
5
Show member pathways
12.53 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
6
Show member pathways
12.5 IRF3 IFNB1 IFNAR1 IFNA1 BST2
7 12.48 RIGI IRF3 IFNA1 IFIH1 CD8A
8
Show member pathways
12.41 RIGI IRF3 IFIH1 BST2 ACE2
9
Show member pathways
12.35 RIGI IRF3 IFNB1 IFNA1 IFIH1
10
Show member pathways
12.28 RIGI IRF3 IFNB1 IFNA1
11
Show member pathways
12.19 RIGI IRF3 IFNB1 IFNAR1 IFNA1 IFI30
12
Show member pathways
11.98 IFNB1 IFNAR1 DAG1 CD8A CD4
13 11.97 BST2 CD209 IRF3 RIGI
14 11.9 LAMP1 CD8A CD4 CD209
15 11.73 IFNB1 IFNAR1 IFNA1
16
Show member pathways
11.66 IFNB1 CD8A CD4 ACE2
17 11.6 IFNB1 CD8A CD4 CD209
18 11.33 RIGI IRF3 IFNB1 ACE2
19
Show member pathways
11.08 RIGI IRF3 IFNB1 IFNAR1 IFIH1 ACE2
20 10.54 IFIH1 IRF3 RIGI
21 10.46 RIGI IRF3 IFNB1 IFIH1

GO Terms for Lassa Fever

Cellular components related to Lassa Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.33 ACE2 BST2 CD209 CD4 CD8A DAG1
2 membrane GO:0016020 10.33 ACE2 BST2 CD209 CD4 CD8A DAG1
3 external side of plasma membrane GO:0009897 9.7 LAMP1 GP2 DAG1 CD8A CD4 CD209
4 membrane raft GO:0045121 9.28 GP2 DAG1 CD4 BST2 ACE2

Biological processes related to Lassa Fever according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 10.21 RIGI IRF3 IFNB1 IFNA1 IFIH1 BST2
2 cytosolic pattern recognition receptor signaling pathway GO:0002753 10.13 RIGI IFIH1
3 cytosolic pattern recognition receptor signaling pathway GO:0039528 10.13 RIGI IFIH1
4 response to virus GO:0009615 10.1 BST2 IFIH1 IFNAR1 IFNB1 RIGI
5 viral entry into host cell GO:0046718 10.02 LAMP1 DAG1 CD4 CD209 ACE2
6 negative regulation of viral genome replication GO:0045071 10.01 IFNB1 IFIH1 BST2
7 positive regulation of interferon-beta production GO:0032728 9.99 RIGI IRF3 IFIH1
8 type I interferon-mediated signaling pathway GO:0060337 9.97 IRF3 IFNB1 IFNAR1 IFNA1
9 positive regulation of interferon-alpha production GO:0032727 9.95 IFIH1 IRF3 RIGI
10 positive regulation of response to cytokine stimulus GO:0060760 9.87 RIGI IFIH1
11 detection of virus GO:0009597 9.85 RIGI IFIH1
12 cellular response to virus GO:0098586 9.85 IRF3 IFNB1 IFNAR1 IFNA1 IFIH1
13 MDA-5 signaling pathway GO:0039530 9.8 IRF3 IFIH1
14 response to exogenous dsRNA GO:0043330 9.8 IFNA1 IFNB1 IRF3 RIGI
15 regulation of type III interferon production GO:0034344 9.76 RIGI IFIH1
16 defense response to other organism GO:0098542 9.56 RIGI IFIH1
17 cellular response to exogenous dsRNA GO:0071360 9.56 RIGI IRF3 IFNB1 IFIH1
18 immune system process GO:0002376 9.32 RIGI IRF3 IFIH1 IFI30 GP2 CD8A

Molecular functions related to Lassa Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.32 LAMP1 DAG1 CD4 CD209 ACE2

Sources for Lassa Fever

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....